AJANTPHARM:NSE-Ajanta Pharma Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 2,161.95

Change

-49.25 (-2.23)%

Market Cap

INR 191.35B

Volume

0.07M

Avg Analyst Target

INR 2,491.25 (+15.23%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets finished dosages. The company markets and serves various therapeutic segments, such as anti-biotic, anti-malarial, anti-diabetic, cardiology, gynecology, pediatric, respiratory and general health products, dermatology, ophthalmology, and pain management areas. It also provides multivitamins, antibiotics, eye drops, cough syrups, etc. The company serves in India, Africa, rest of Asia, the United States, and internationally. It supplies its products to government bodies, including armed forces, government hospitals, canteens, stores department, etc. The company was founded in 1973 and is headquartered in Mumbai, India. Address: Ajanta House, Mumbai, India, 400067

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-19 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

-8.55 (-1.02%)

INR2,005.60B 33.44 21.56
DIVISLAB:NSE Divi's Laboratories Limited

-150.95 (-2.83%)

INR1,418.41B 69.21 43.47
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

-75.70 (-1.55%)

INR809.18B 47.29 21.18
PEL:NSE Piramal Enterprises Limited

-70.05 (-2.49%)

INR672.50B 48.98 11.87
CADILAHC:NSE Cadila Healthcare Limited

-7.20 (-1.35%)

INR547.09B 24.12 17.94
ALKEM:NSE Alkem Laboratories Limited

-19.15 (-0.50%)

INR461.68B 28.31 21.09
LUPIN:NSE Lupin Limited

+1.95 (+0.21%)

INR425.18B 25.81 14.15
AUROPHARMA:NSE Aurobindo Pharma Limited

-5.70 (-0.79%)

INR420.85B 7.90 5.01
LAURUSLABS:NSE Laurus Labs Limited

-28.15 (-4.36%)

INR346.19B 33.02 21.30
IPCALAB:NSE Ipca Laboratories Limited

-73.45 (-3.04%)

INR306.42B 30.59 20.49

ETFs Containing AJANTPHARM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 30.94% 54% F 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.94% 52% F 37% F
Trailing 12 Months  
Capital Gain 37.28% 43% F 23% F
Dividend Return 0.60% 54% F 24% F
Total Return 37.88% 45% F 23% F
Trailing 5 Years  
Capital Gain 9.65% 33% F 45% F
Dividend Return 2.26% 49% F 30% F
Total Return 11.91% 33% F 44% F
Average Annual (5 Year Horizon)  
Capital Gain 9.41% 26% F 46% F
Dividend Return 0.72% 79% C+ 51% F
Total Return 10.13% 25% F 45% F
Risk Return Profile  
Volatility (Standard Deviation) 33.96% 83% B 79% C+
Risk Adjusted Return 29.82% 35% F 58% F
Market Capitalization 191.35B 85% B 86% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 28.26 45% F 41% F
Price/Book Ratio 6.65 27% F 17% F
Price / Cash Flow Ratio 33.20 27% F 19% F
EV/EBITDA 18.81 44% F 37% F
Management Effectiveness  
Return on Equity 23.38% 76% C 88% B+
Return on Invested Capital 22.55% 82% B- 92% A-
Return on Assets 15.71% 93% A 97% A+
Debt to Equity Ratio 0.05% 80% B- 85% B
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta -0.19 97% A+ 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector